

GenCore version 4.5
Copyright (c) 1993 - 2000 Compugen Ltd.

OM protein - protein search, using sw model

Run on: May 7, 2002, 12:00:48 ; Search time 53.91 Seconds
(without alignments)
175.874 Million cell updates/sec

Title: US-09-772-103-8

Perfect score: 655

Sequence: 1 MDPVQIFSLISASVILS.....CQWSSYPLTFGGTKVIEK 128

Scoring table:

BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 522463 seqs, 74073290 residues

al number of hits satisfying chosen parameters: 522463

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

A_Geneseq_1101.*

1: /SID88/gcgdata/geneseq/geneseq/AA1980.DAT.*
2: /SID88/gcgdata/geneseq/geneseq/AA1981.DAT.*
3: /SID88/gcgdata/geneseq/geneseq/AA1982.DAT.*
4: /SID88/gcgdata/geneseq/geneseq/AA1983.DAT.*
5: /SID88/gcgdata/geneseq/geneseq/AA1984.DAT.*
6: /SID88/gcgdata/geneseq/geneseq/AA1985.DAT.*
7: /SID88/gcgdata/geneseq/geneseq/AA1986.DAT.*
8: /SID88/gcgdata/geneseq/geneseq/AA1987.DAT.*
9: /SID88/gcgdata/geneseq/geneseq/AA1988.DAT.*
10: /SID88/gcgdata/geneseq/geneseq/AA1989.DAT.*
11: /SID88/gcgdata/geneseq/geneseq/AA1990.DAT.*
12: /SID88/gcgdata/geneseq/geneseq/AA1991.DAT.*
13: /SID88/gcgdata/geneseq/geneseq/AA1992.DAT.*
14: /SID88/gcgdata/geneseq/geneseq/AA1993.DAT.*
15: /SID88/gcgdata/geneseq/geneseq/AA1994.DAT.*
16: /SID88/gcgdata/geneseq/geneseq/AA1995.DAT.*
17: /SID88/gcgdata/geneseq/geneseq/AA1996.DAT.*
18: /SID88/gcgdata/geneseq/geneseq/AA1997.DAT.*
19: /SID88/gcgdata/geneseq/geneseq/AA1998.DAT.*
20: /SID88/gcgdata/geneseq/geneseq/AA1999.DAT.*
21: /SID88/gcgdata/geneseq/geneseq/AA2000.DAT.*
22: /SID88/gcgdata/geneseq/geneseq/AA2001.DAT.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	655	100.0	128	22	AA66522
2	609	93.0	128	17	AA90684
3	600	91.6	128	21	AA77597
4	600	91.6	128	22	AA77866
5	599	91.5	128	18	AAW41398
6	593	90.5	235	18	AAW41411
7	590	90.1	133	15	AA953445
8	590	90.1	133	20	AA28394
9	590	90.1	133	20	AA28371
10	587	89.6	126	21	AA77599
11	587	89.6	126	22	AA78868
					Humanised anti-CTL
					Humanised 5C7.29 a
					Anti-human VEGF re
					Anti-human Fit-1 a
					Humanised antibody
					Humanised light ch
					REI human Ab L cha
					Anti-GM2 light cha
					Intermediate seque
					Anti-human VEGF re
					Anti-human Fit-1 a

12	584	89.2	130	19	AAW73179
13	584	89.2	130	19	AAW73180
14	584	89.2	130	20	AAV28375
15	584	89.2	130	20	AAV28376
16	583	89.0	235	18	AAW41410
17	580	88.5	130	19	AAW73181
18	580	88.5	130	20	AAW73182
19	573	87.5	126	21	AA77601
20	573	87.5	126	22	AA77601
21	572	87.3	130	19	AAW73182
22	572	87.3	130	20	AAW73182
23	571	87.2	130	19	AAW73185
24	571	87.2	130	20	AAW73185
25	568	86.7	130	19	AAW73184
26	568	86.7	130	20	AAW73184
27	567	86.6	130	19	AAW73173
28	567	86.6	130	20	AAW73173
29	566	86.4	130	21	AAW73176
30	566	86.4	130	22	AAW73176
31	562	85.8	130	19	AAW73183
32	562	85.8	130	20	AAW73183
33	560	85.5	130	19	AAW73174
34	560	85.5	130	20	AAW73174
35	543	82.9	235	17	AAW06180
36	528	80.6	128	22	AA66521
37	523	79.8	235	18	AAW41392
38	520	79.4	126	21	AA77598
39	520	79.4	126	22	AA77598
40	520	79.4	128	13	AA27050
41	519	79.2	128	22	AA66555
42	518	79.1	126	19	AAW36164
43	517	78.9	128	12	AAW12327
44	516	78.8	129	17	AA886108
45	514	78.5	128	17	AA90690

ALIGNMENTS

RESULT 1

AA66522

ID AAG66522 standard; Protein; 128 AA.

XX AAG66522;

AC AAG66522;

XX 22-OCT-2001 (first entry)

DT Humanised anti-CTLA4 light chain.

DE Human; CTLA4; cytotoxic T lymphocyte associated antigen 4; anti-CTLA4;

KW immunosuppressive; immunomodulator; antiallergic; vaccine; antibody;

KW T cell; humanised antibody; autoimmune disorder; graft rejection;

KW allergy; light chain.

XX Homo sapiens.

OS Mus musculus.

XX Synthetic.

XX WO200154732-A1.

XX 02-AUG-2001.

XX 26-JAN-2001; 2001WO-US02653.

XX 27-JAN-2000; 2000US-0178473.

XX (GEM) GENETICS INST INC.

XX Carreno BM, Wood C, Turner K, Collins M, Gray GS, Morris D;

XX O'Hara D, Hinton P, Tsurushita N;

XX WPT; 2001-483195/52.

XX N-PSDB; AAH76440, AAH76442.

XX Mus musculus.
 OS WO9960025-A1.
 PN 25-NOV-1999.
 PD
 PF 20-MAY-1999; 99WO-JP02661.
 PR 20-MAY-1998; 98JP-0139000.
 XX (KYOW) KYOWA HAKKO KOGYO KK.
 PA Shitara K, Ito M, Kawada Y, Nakamura K;
 PI WPI; 2000-072431/06.
 DR N-PSDB; AAZ87745.
 XX
 PT Gene recombinant antibodies, useful for diagnosis and as remedies for diseases due to abnormal neovascularization e.g. proliferation or metastasis of solid tumor, rheumatoid arthritis, diabetic retinopathy and psoriasis -
 CC Claim 27; Page 200-201; 210pp; Japanese.
 CC The invention relates to a gene recombinant antibody that has specific reaction with human vascular endothelial growth factor (VEGF) receptor FIt-1. The antibodies are useful for diagnosis and as remedies for diseases due to abnormal neovascularization such as proliferation or metastasis of solid tumor, arthritis in rheumatoid arthritis, diabetic retinopathy, premature retinopathy and psoriasis.
 CC Sequence 128 AA;
 SQ

Query Match
 Best Local Similarity 91.6%; Score 600; DB 21; Length 128;
 Matches 117; Conservative 5; Mismatches 6; Indels 0; Gaps 0;

QY 1 MDFQVQIFSFLLISAVILSRGDIQTQSPSSLSASVGDRTITCSATSSITVMSWYQOK 60
 DB 1 mdfqvqifsfllisavilsrgdiqmtqspsslsasvgrvrtitcsassvsymhwyqk 60
 QY 61 PGKAPKLLIYDTNLSAGVPSRFGSGGTDYTLTSSLOPEDFATYYCQWSSVPLTFG 120
 DB 61 pgkapklliydtkslpsgvpfrfsgsgtdftltsslqpedfatyyccqwsnptfg 120
 QY 121 GGTKVEIK 128
 DB 121 qgtkveik 128

RESULT 4
 AAB78866
 ID AAB78866 standard; Protein; 128 AA.
 AC AAB78866;
 XX
 DT 20-APR-2001 (first entry)
 DE Anti-human FIt-1 antibody VL CDR protein sequence SEQ ID 88.
 KW Differentiation; monocyte; macrophage; haematopoietic stem cell; cancer;
 KW vascular endothelial growth factor; VEGF; FIt-1; inflammation; antibody;
 KW delayed hypersensitivity; malignant tumour; arteriosclerosis.
 OS Synthetic.
 XX
 PN WO200079275-A1.
 XX 28-DEC-2000.
 PD
 PF 16-JUN-2000; 2000WO-JP03957.

XX
 PR 17-JUN-1999; 99JP-0171709.
 PA (KYOW) KYOWA HAKKO KOGYO KK.
 XX Shitara K, Shibuya M;
 PI WPI; 2001-080847/09.
 DR N-PSDB; AAF70222.
 XX
 PT Substances binding to human vascular endothelial growth factor receptor FIt-1, used for diagnosis and treatment of inflammatory diseases, arteriosclerosis, cancer and delayed hypersensitivity -
 CC Example 3; Page 156; 164pp; Japanese.
 CC This invention relates to a reagent for detecting differentiation of monocytes and macrophages from haematopoietic stem cells, containing a substance which binds to human vascular endothelial growth factor (VEGF) receptor FIt-1. The invention also includes a method for diagnosing a disease in which the differentiation of monocytes and macrophages is implicated, using the reagent, and an agent for the treatment of diseases diagnosed using the method, containing a substance which binds to FIt-1 or a substance which inhibits the signal transduction of FIt-1. Diseases which may be diagnosed or treated include inflammation, delayed hypersensitivity, malignant tumours and arteriosclerosis.
 CC AAF70190 - AAF70244, AAF70251 and AAF70258 represent DNA sequences encoding anti-human FIt-1 monoclonal antibody fragments, and oligonucleotides used in the construction of the antibody. The monoclonal antibody is used in the reagent of the invention. PCR primers AAF70245 - AAF78870 (excluding AAF70251) are used in the isolation of the antibody DNA sequences. Protein sequences AAB78848 - AAB78870 represent fragments of the anti-human FIt-1 antibody.
 CC Sequence 128 AA;
 SQ

Query Match
 Best Local Similarity 91.6%; Score 600; DB 22; Length 128;
 Matches 117; Conservative 5; Mismatches 6; Indels 0; Gaps 0;

QY 1 MDFQVQIFSFLLISAVILSRGDIQTQSPSSLSASVGDRTITCSATSSITVMSWYQOK 60
 DB 1 mdfqvqifsfllisavilsrgdiqmtqspsslsasvgrvrtitcsassvsymhwyqk 60
 QY 61 PGKAPKLLIYDTNLSAGVPSRFGSGGTDYTLTSSLOPEDFATYYCQWSSVPLTFG 120
 DB 61 pgkapklliydtkslpsgvpfrfsgsgtdftltsslqpedfatyyccqwsnptfg 120
 QY 121 GGTKVEIK 128
 DB 121 qgtkveik 128

RESULT 5
 AAW41398
 ID AAW41398 standard; Protein; 235 AA.
 AC AAW41398;
 XX
 DT 02-JUN-1998 (first entry)
 DE Humanised antibody 806.077 variable light chain.
 KW Anti-CEA antibody; carcinoembryonic antigen; 806.077 Ab; cancer therapy;
 KW cancer diagnosis; complementarity determining region; Fd chain.
 OS Chimeric - Homo sapiens.
 OS Chimeric - Mus sp.
 PN WO9742329-A1.
 XX 13-NOV-1997.
 PD

XX	Copley CG, Edge MD, Emery SC;
PI	WPT: 1997-558987/51.
DR	N-PSDB: AAVI7315.
XX	Anti-carcinoembryonic antigen antibody 806.077 Ab - used for
XX	diagnosis and therapy of cancer
XX	Example 45; Page 164-165; 208pp; English.
XX	This sequence is the HuVK4-HuCK light chain of the antibody of
CC	the invention. The antibody is an anti-CEA (carcinoembryonic antigen)
CC	antibody (806.077 Ab). Host cells or transgenic organisms transformed
CC	with DNA encoding the antibody, are used to make the antibody or
CC	conjugate. The conjugate is used in a medicament suitable for intravenous
CC	administration. The conjugate can be used for cancer therapy, selectively
CC	killing tumour cells. The antibody can be used for in vivo or in vitro
CC	diagnosis of cancer.
XX	Sequence 235 AA;
SQ	
	Query Match 90.5%; Score 593; DB 18; Length 235;
	Best Local Similarity 90.6%; Pred. No. 7.7e-37; Indels 0; Gaps 0;
	Matches 116; Conservative
QY	1 MDFQVQIFSLIASVILSRGDIQTQSPSSLSASVGDRVITCSATGSSTIYMSWYQOK 60
Dd	1 mdfqvqifslisasvmsrgdlqntqpsslsasvgdrvltcsassvtymhwgqk 60
QY	61 PGKAPKLIIYDTSNLACGVPRFSGSGSDTYLTITSSLQPEDFAIYYCQOWSSYPLTFG 120
Dd	61 pgkapklwystsnlasgvprfsgsgsdtylftisslqpediaiyycqrstyppltfg 120
QY	121 GGTKVEIK 128
Dd	121 qgtkleik 128
RESULT	7
AAR53345	
ID	AAR53345 standard; Protein; 133 AA.
XX	
AC	AAR53345;
XX	
DT	18-NOV-1994 (first entry)
XX	
DE	REI human Ab L chain variable region.
XX	
KW	Monoclonal antibody; Ab; ganglioside GM2; chimera;
KW	chimeric antibody; expression vector; heavy; light; chain;
KW	hypervariable region; CDR; constant region; hybridoma;
KW	Ig; immunoglobulin; promoter; enhancer.
XX	
OS	Synthetic.
XX	
FH	Location/Qualifiers
FT	Key 1..22
FT	Peptide /label= sig_peptide
XX	
PX	AU9346181-A.
PN	
PD	17-MAR-1994.
XX	
DF	07-SEP-1993; 93AU-0046181.
XX	
FR	07-SEP-1992; 92JP-0238452.
XX	
PA	(KYOW) KYOWA HAKKO KOGYO KK.
XX	
PI	Hanai N, Hasegawa M, Koike M, Kuwana Y, Nakamura K;
PI	Shitara K;

29-APR-1997; 97WO-GB01165.
14-FEB-1997; 97GB-0003103.
04-MAY-1996; 96GB-0009405.
(ZENE) ZENECA LTD.
Copley CG, Edge MD, Emery SC;
WPI; 1997-558987/51.
N-PSDB; AAV172971.
Anti-carcinoembryonic antigen antibody 806.077 Ab - used for
diagnosis and therapy of cancer
Example 11; Page 124-125; 208pp; English.
This sequence is the light chain variable region of the antibody of
the invention. The antibody is an anti-CEA (carcinoembryonic antigen)
antibody (806.077 Ab). Host cells or transgenic organisms transfected
with DNA encoding the antibody, are used to make the antibody or
conjugate. The conjugate is used in a medicament suitable for intravenous
administration. The conjugate can be used for cancer therapy, selectively
killing tumour cells. The antibody can be used for in vivo or in vitro
diagnosis of cancer.
Sequence 235 AA;
Query Match 91.5%; Score 599; DB 18; Length 235;
Best Local Similarity 91.4%; Pred. No. 2.8e-37;
Matches 117; Conservative 5; Mismatches 6; Indels 0; Gaps 0;
QY 1 MDFQVQIFSLISASVILSRGDIQMTQSPSSLSASVGRVITTCSATSSITYKSWYQOK 60
Db 1 mdftqdfllfllisaavimrgdiqmtqspssalsasvgrviticasssvlymhwyqk 60
QY 61 PGKAPKLLIYDTNLSAGVPSRFSGSGCTDYTLTISSLQPEDFATYYCQOWSSYPLTFG 120
Db 61 pgkapklliydstnlasgvpvrsfsgsgtdyfttisslqpeditatycyqgrstypftfg 120
QY 121 GGTKVEIK 128
Db 121 qgtkieik 128
RESULT 6
AAW41411 standard; Protein; 235 AA.
AAW41411;
02-JUN-1998 (first entry)
Humanised light chain HuVK4-HuCK.
Anti-CEA antibody; carcinoembryonic antigen; 806.077 Ab; cancer therapy;
cancer diagnosis; complementarity determining region; Fd chain.
Chimeric - Homo sapiens.
Chimeric - Mus sp.
WO9742329-A1.
13-NOV-1997.
29-APR-1997; 97WO-GB01165.
14-FEB-1997; 97GB-0003103.
04-MAY-1996; 96GB-0009405.
(ZENE) ZENECA LTD.

XX WPI; 1994-126857/16.
 DR N-PSDB; AAQ77823.
 XX
 PT Humanised antibody specific for ganglioside GM2 - used for
 PT producing a cytotoxic effect on cancers such as melanoma,
 PT neuroblastoma and glioma.
 XX
 PS Example 2; Page 122-123; 191pp; English.
 XX
 CC REI was used as human Ab L chain variable region-encoding
 CC DNA to which CDRs were to be transplanted. DNAs given in
 CC AAQ63448-53 were synthesised and ligated in order to obtain
 CC a DNA, hK796L (AAQ77823).
 XX
 SQ Sequence 133 AA;

Query Match 90.1%; Score 590; DB 15; Length 133;
 Best Local Similarity 89.8%; Pred. No. 7.5e-37;
 Matches 115; Conservative 6; Mismatches 7; Indels 0; Gaps 0;
 QY 1 MDFQVQIFSLISASVILSRGDIQMTQSPSSLSASVGDRTVITCSATSSITYSWYQOK 60
 Db 1 mhifqvqifslisavimsrgdqltqspsslsasvgsdrtvtitcsasssvsynhywqgk 60
 QY 61 PGKAPKLLIYDTSNLASGVPSRFSGSGCTDYTLTISLQPEDFATYICQWSSYPLTFG 120
 Db 61 pgkapklliydstnlasgvpssrfsgsgtdfttisslqpdiatyycqgrssypytfg 120
 QY 121 GGTKEIK 128
 Db 121 ggtkveik 128

RESULT 8
 AAY28394
 ID AAY28394 standard; Protein; 133 AA.
 AC AAY28394;
 DT 04-NOV-1999 (first entry)
 DE Anti-GM2 light chain hK796L ligation product.
 KW antibody; nucleotide; genomic; hypervariable region;
 KW chimeric; light chain; heavy chain; plasmid; ligation product.
 XX Synthetic.
 XX Homo sapiens.
 PN US5939532-A.
 XX 17-AUG-1999.
 PD 07-JUN-1995; 95US-0483528.
 PF 07-JUN-1995; 95US-0483528.
 PR 07-SEP-1993; 93US-0116778.
 XX (KYOW) KYOWA HAKKO KOGYO KK.
 PA Hanai N, Hasegawa M, Koike M, Kuwana Y, Nakamura K;
 PI Shitara K;
 XX WPI; 1999-468416/39.
 DR Chimeric human antibody expression vectors
 XX Example 2; Column 159-161; 188pp; English.
 PS This is the ligation product formed when peptide fragments AAY28390 to
 CC AAY28392 replace the complementarity determining regions of REI.

CC Chimeric human antibodies of the invention are useful in the treatment
 CC of cancer, especially that which is of neural ectodermal origin.
 CC In contrast to prior art constructs based on mouse monoclonal
 CC immunoglobulin production.
 CC The chimeric human antibodies have a prolonged half-life and a reduced
 CC frequency of adverse effects when compared to mouse monoclonal
 CC antibodies.
 XX
 SQ Sequence 133 AA;

Query Match 90.1%; Score 590; DB 20; Length 133;
 Best Local Similarity 89.8%; Pred. No. 7.5e-37;
 Matches 115; Conservative 6; Mismatches 7; Indels 0; Gaps 0;
 QY 1 MDFQVQIFSLISASVILSRGDIQMTQSPSSLSASVGDRTVITCSATSSITYSWYQOK 60
 Db 1 mhifqvqifslisavimsrgdqltqspsslsasvgsdrtvtitcsasssvsynhywqgk 60
 QY 61 PGKAPKLLIYDTSNLASGVPSRFSGSGCTDYTLTISLQPEDFATYICQWSSYPLTFG 120
 Db 61 pgkapklliydstnlasgvpssrfsgsgtdfttisslqpdiatyycqgrssypytfg 120
 QY 121 GGTKEIK 128
 Db 121 ggtkveik 128

RESULT 9
 AAY28371
 ID AAY28371 standard; Protein; 133 AA.
 AC AAY28371;
 DT 04-NOV-1999 (first entry)
 DE Intermediate sequence in the construction of human antibodies.
 KW immunoglobulins; antibody; chimeric; vector; expression;
 KW light chain; heavy chain; amino acid.
 XX Mammalia sp.
 XX US5939532-A.
 XX 17-AUG-1999.
 PD 07-JUN-1995; 95US-0483528.
 PF 07-JUN-1995; 95US-0483528.
 PR 07-SEP-1993; 93US-0116778.
 XX (KYOW) KYOWA HAKKO KOGYO KK.
 PA Hanai N, Hasegawa M, Koike M, Kuwana Y, Nakamura K;
 PI Shitara K;
 XX WPI; 1999-468416/39.
 DR N-PSDB; AAX99497.
 XX Chimeric human antibody expression vectors
 XX Disclosure; Column 109; 188pp; English.
 PS This sequence is forms a stage in the production of anti-GM2 human
 CC chimeric antibodies.
 CC The chimeric human antibodies are useful in the treatment of
 CC cancer, especially that which is of neural ectodermal origin.
 CC In contrast to prior art constructs based on mouse monoclonal antibodies,
 CC the chimeric human antibodies do not cause anti-mouse immunoglobulin
 CC production.
 CC The chimeric human antibodies have a prolonged half-life and a

Query Match	89.6%;	Score 587;	DB 22;	Length 126;
Best Local Similarity	90.6%;	Pred. No. 1.2e-36;		
Matches 116;	Conservative 5;	Mismatches 5;	Indels 2;	Gaps
1	MDFOVQVIFSPLLISASVILSRGDIQMTQSPSLSASVGRVTITCSATSSITVMSYQQR	60		
1	mdfgvqvfllisavilsgdiqmtqspsslsasvgrvtticssasvsymhwyyqk	60		
61	PGKAPKLLIYDTSNLASGVPSRFGSGSGGTDTYTLTISLQPEDFATVYCOOWSSYPLTRG	120		
61	pgkapklllyrtsnlasgvpsrfgsgsggtftitisslqpedafatyqchqwsmy--tfg	118		
121	GGTKVEIK	128		
119	qgtkveik	126		

RESULT 12
AAW73179
AAW73179 standard; Protein; 130 AA.
AAW73179;
22-JAN-1999 (first entry)
Fragment of ganglioside GM2 targeting antibody.
Ganglioside GM2; antibody; complementarity determining region; cancer;
anti-tumour agent.

Db	61	pgkapklllystsnlsgvpsrfsgsgtdftfisslqpediatyvcqgrsspytf	120
Qy	121	GGKVEIK	128
Db	121	ggtkveik	128
RESULT 13			
AAW73180			
ID	AAW73180 standard; Protein; 130 AA.		
XX			
AC	AAW73180;		

RESULT	14
AAAY28375	
ID	AAAY28375 standard; Protein; 130 AA.

us-09-772-103-8.rag

Mon Jul 1 16:28:11 2002

61 pgkapklliystnlasgvpfrsfsgsgtdfttisslqpediatyycqrrssypytfg 120

Db 121 GGTKEIK 128
QY 121 GGTKEIK 128
Db 121 GGTKEIK 128

RESULT 15
AAY28376
ID AAY28376 standard; Protein; 130 AA.
XX
AC AAY28376;
XX
DT 04-NOV-1999 (first entry)
XX
DE Human chimeric anti-GM2 light chain version 2.
XX
KW antibody; nucleotide; genomic; hypervariable region;
KW chimeric; light chain; heavy chain; CDR; plasmid;
KW complementarity determining region.
XX
OS Chimeric - Homo sapiens.
OS Chimeric - Mus sp.
XX
FH Key Location/Qualifiers
FT Peptide 1..22
FT /label= "signal peptide"
FT Protein 23..130
FT /label= "Mature heavy chain"
FT Domain 46..55
FT /label= "CDR1"
FT Domain 71..77
FT /label= "CDR2"
FT Domain 100..108
FT /label= "CDR3"
FT /note= "Complementarity determining region"
XX
PN US5939532-A.
XX
PD 17-AUG-1999.
XX
PF 07-JUN-1995; 95US-0483528.
XX
PR 07-JUN-1995; 95US-0483528.
PR 07-SEP-1993; 93US-0116778.
XX
PA (KYOW) KYOWA HAKKO KOGYO KK.
XX
XX Hanai N, Hasegawa M, Koike M, Kuwana Y, Nakamura K;
PI Shitara K;
XX
XX WPI; 1999-468416/39.
DR N-PSDB; AAZ06278.
XX
XX Chimeric human antibody expression vectors
XX
PS Example 3; Column 125-127; 188pp; English.
XX
XX This is the amino acid sequence derived from AAZ06275, which can be amplified from the plasmid pBSL16 by the mutant primers AAZ06273 and AAZ06274.
CC Chimeric human antibodies of the invention are useful in the treatment of cancer, especially that which is of neural ectodermal origin.
CC In contrast to prior art constructs based on mouse monoclonal antibodies, the chimeric human antibodies do not cause anti-mouse immunoglobulin production.
CC the chimeric human antibodies have a prolonged half-life and a reduced frequency of adverse effects when compared to mouse monoclonal antibodies.
XX
SQ Sequence 130 AA;

Query Match
Best Local Similarity 89.1%; Pred. No. 2e-36; 8; Indels 0; Gaps 0;
Matches 114; Conservative 6; Mismatches 8; Length 130;
QY 1 MDEFQVIFSLISAVTLRGDTQMTQSPSSLSASVGVDRVTTCATSSITVMSYQOK 60
Db 1 mhfvqifslisavtlrsgdltqspsslsaspgdrvtitcsassvymhwqqk 60
QY 61 AGKAPKLLIYDTSNLSASGVPFRSFGSGTDTLTITSLQPEDFATYICQOWSSYPLTFG 120


```

Query Match      89.2%  Score 584; DB 20; Length 130;
Best Local Similarity 89.1%  Pred. No. 2e-36;
Matches 114; Conservative 6; Mismatches 8; Indels 0; Gaps 0;

QY 1 MDFOVQIFSELLISASVILSRGDIQMTQSPSSLSASVGRVTITCSATSSITVMSWYQOK 60
   | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Db 1 mhfvqqlflllasvimsrgdqltqpslslasvgrvrtitcsasssvymhwgqk 60
   | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
QY 61 PGKAPKLLIYDTSNLSAGVPSRFSGSGTDYTLTISSLPQEDFATYYCQWSSYPLTFG 120
   | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Db 61 pgkapklwiystnlasgvpfrfsgsgtdfttisslqpediatyyccqgrssypytfg 120
   | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
QY 121 GGNKVEIK 128
   | | | | | | | |
Db 121 gntkveik 128

```

Search completed: May 7, 2002, 12:00:48
 time: 126 sec

